{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:24Z","timestamp":1791328884365,"version":"4.3.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/fjc.0000000000000366","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T12:49:42Z","timestamp":1455022182000},"page":"402-411","source":"Crossref","is-referenced-by-count":84,"title":["Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy"],"prefix":"10.1097","volume":"67","author":[{"given":"Jana","family":"Grune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janek","family":"Salatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelie","family":"Blumrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"H\u00f6ft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klopfleisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Foryst-Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kintscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210208","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"R2-7-20210208","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0008-6363(99)00088-7","article-title":"Aldosterone and the heart: towards a physiological function?","volume":"43","author":"Delcayre","year":"1999","journal-title":"Cardiovasc Res"},{"key":"R3-7-20210208","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"R4-7-20210208","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-7-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R6-7-20210208","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"R7-7-20210208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-7-20210208","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/14728222.2013.748750","article-title":"Targeting the mineralocorticoid receptor in cardiovascular disease","volume":"17","author":"Young","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"R9-7-20210208","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"R10-7-20210208","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"Chem Med Chem"},{"key":"R11-7-20210208","doi-asserted-by":"crossref","first-page":"R1597","DOI":"10.1152\/ajpregu.00825.2009","article-title":"Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload","volume":"298","author":"Fliegner","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R12-7-20210208","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1440-1681.2006.04434.x","article-title":"Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice","volume":"33","author":"Franco","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R13-7-20210208","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"R14-7-20210208","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ Res"},{"key":"R15-7-20210208","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/jps.10588","article-title":"High-throughput determination of the free fraction of drugs strongly bound to plasma proteins","volume":"93","author":"Schuhmacher","year":"2004","journal-title":"J Pharm Sci"},{"key":"R16-7-20210208","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tvjl.2010.10.018","article-title":"The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas","volume":"190","author":"Klopfleisch","year":"2011","journal-title":"Vet J"},{"key":"R17-7-20210208","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1021\/pr200112q","article-title":"Is there a malignant progression associated with a linear change in protein expression levels from normal canine mammary gland to metastatic mammary tumors?","volume":"10","author":"Klose","year":"2011","journal-title":"J Proteome Res"},{"key":"R18-7-20210208","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor Coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"R19-7-20210208","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2011.159","article-title":"Mechanisms of disease: hypertrophic cardiomyopathy","volume":"9","author":"Frey","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"R20-7-20210208","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrd4554","article-title":"Targeting the sarcomere to correct muscle function","volume":"14","author":"Hwang","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"R21-7-20210208","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur Heart J"},{"key":"R22-7-20210208","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.HYP.0000258532.07418.fa","article-title":"Molecular biology of the natriuretic peptide system: implications for physiology and hypertension","volume":"49","author":"Gardner","year":"2007","journal-title":"Hypertension"},{"key":"R23-7-20210208","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.RES.0000094745.28948.4D","article-title":"Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A","volume":"93","author":"Kuhn","year":"2003","journal-title":"Circ Res"},{"key":"R24-7-20210208","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1073\/pnas.051625598","article-title":"A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy","volume":"98","author":"Kishimoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-7-20210208","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1161\/CIRCULATIONAHA.104.510594","article-title":"Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides","volume":"111","author":"Tokudome","year":"2005","journal-title":"Circulation"},{"key":"R26-7-20210208","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/CIRCULATIONAHA.110.981720","article-title":"Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats","volume":"123","author":"Cataliotti","year":"2011","journal-title":"Circulation"},{"key":"R28-7-20210208","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","article-title":"Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload","volume":"111","author":"Kuster","year":"2005","journal-title":"Circulation"},{"key":"R29-7-20210208","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R30-7-20210208","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCHEARTFAILURE.112.000123","article-title":"A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R31-7-20210208","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCHEARTFAILURE.113.000713","article-title":"Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A","volume":"7","author":"Maejima","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R32-7-20210208","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1093\/eurheartj\/ehv294","article-title":"Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy","volume":"36","author":"Guo","year":"2015","journal-title":"Eur Heart J"},{"key":"R33-7-20210208","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FJC.0b013e31827fe59c","article-title":"Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice","volume":"61","author":"Morgan","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"R34-7-20210208","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"R35-7-20210208","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R36-7-20210208","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000371497","article-title":"Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy","volume":"40","author":"Ruilope","year":"2014","journal-title":"Am J Nephrol"},{"key":"R37-7-20210208","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:13:30Z","timestamp":1620951210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-201605000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000366","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}